Novo Nordisk: Back To Business As Usual

About: Novo Nordisk A/S (NVO)
by: Daniel Schönberger
This article is exclusive for subscribers.
Daniel Schönberger
Value, long-term horizon, dividend investing, long only

Although earnings per share grew only 2%, Novo Nordisk reported solid results with 9% revenue growth and 11% operating income growth.

Saxenda, Ozempic and Rybelsus will contribute to revenue growth in the years to come.

Novo Nordisk has a wide economic moat based on the different patents and also high barriers to entry combined with a market-leading position.

When using moderate and realistic growth rates, Novo Nordisk seems to be fairly valued right now and should yield at least about 10% going forward.

Last week, Novo Nordisk (NVO) reported third-quarter results and despite still existing challenges, it seems the company is back on track and the steady performer again it was for several years. In the